Hypertension is an important risk factor for cardiovascular disease,^[@CIT0001]^ the major cause of morbidity and mortality worldwide.^[@CIT0002]^ Effective diagnosis and management of hypertension depends on accurate measurement of blood pressure, which allows appropriate targeting of antihypertensive treatment. Ambulatory blood pressure monitoring (ABPM) is considered to be the "gold standard" measure of blood pressure, because multiple readings are taken and because it is associated with a range of cardiovascular outcomes and end organ damage.^[@CIT0003]^ Ambulatory blood pressure is usually lower than clinic blood pressure^[@CIT0008]^ due to the white coat effect ([Table 1](#T1){ref-type="table"}),^[@CIT0012]^ and as such, clinical guidelines recommend that ABPM (or home) blood pressure targets are 5mm Hg lower than the corresponding clinic values.^[@CIT0013],[@CIT0014]^ However, this "home-clinic blood pressure difference" is not always consistent. In some patients, blood pressures measured at home or with ABPM are higher than would be expected for the corresponding clinic blood pressure, the so-called masked effect ([Table 1](#T1){ref-type="table"}).^[@CIT0015]^ Such patients are likely to be undertreated and have increased target organ damage^[@CIT0016],[@CIT0017]^ with subsequent increased cardiovascular mortality compared to normotensive patients.^[@CIT0018],[@CIT0019]^

###### 

Definitions of the home-clinic blood pressure difference

  Term                                    Definition
  --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Home-clinic blood pressure difference   The difference between blood pressure measured with ABPM or at home (self-monitored) and blood pressure measured in the clinic.
  White coat effect                       A negative home-clinic blood pressure difference. Blood pressure measured with ABPM (or at home) is *lower* than the corresponding clinic blood pressure.
  White coat hypertension                 A negative home-clinic blood pressure difference. Blood pressure measured with ABPM (or at home) is \<135/85mm Hg but the corresponding clinic blood pressure is ≥140/90mm Hg.
  Masked effect                           A positive home-clinic blood pressure difference. Blood pressure measured with ABPM (or at home) is *higher* than the corresponding clinic blood pressure.
  Masked hypertension                     A positive home-clinic blood pressure difference. Blood pressure measured with ABPM (or at home) is ≥135/85mm Hg but the corresponding clinic blood pressure is \<140/90mm Hg.
  Masked uncontrolled hypertension        A positive home-clinic blood pressure difference in patients with a previous diagnosis of hypertension. Blood pressure measured with ABPM (or at home) is ≥135/85mm Hg but the corresponding clinic blood pressure is \<140/90mm Hg (incorrectly suggesting the patient is controlled).

Abbreviation: ABPM, ambulatory blood pressure monitoring.

Clinic blood pressure monitoring is still recommended for initial screening of blood pressure in routine clinical practice,^[@CIT0013],[@CIT0014]^ and thus, identifying those patients most likely to display a white coat or masked effect is important to avoid misdiagnosis and mismanagement of hypertension. There is a large body of literature proposing factors that predict white coat or masked hypertension,^[@CIT0020]^ but no studies have systematically reviewed the evidence. Consequently there is little consensus as to which factors are most important or how they should be used in clinical practice to guide diagnosis and management decisions. The present study aimed to systematically review the literature and establish the most important predictors of a significant home-clinic blood pressure difference to inform interventions that might identify those with discordant clinic and ambulatory blood pressure in routine clinical practice.

METHODS {#s1}
=======

This study systematically reviewed all existing literature examining factors that predict the home-clinic blood pressure difference. The protocol is available in the [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1).

Search strategy {#s2}
---------------

A scoping search was carried out to identify background literature and provide an estimate of the volume of literature on the topic. A search strategy (see [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1)) was then designed for use with MEDLINE and then adapted to run across the following databases: CINAHL (EBSCO), The Cochrane (Wiley) CENTRAL Register of Controlled Trials, EMBASE (Ovid), MEDLINE (Ovid) and MEDLINE In Process (Ovid), Science Citation Index -- Expanded & Conference Proceedings Citation Index -- Science, and The ZETOC (Mimas) database. Searches were carried out up to and including March 2014. In order to capture as broad a range of studies as possible, no language or date limits were applied, although animal studies, letters, comments, and review articles were excluded. In addition to searches of electronic databases, reference lists of studies included in the review were checked to identify any further relevant papers.

Selection of studies and inclusion criteria {#s3}
-------------------------------------------

Two authors (J.P.S. and B.F.) reviewed the titles (10% independently) and abstracts (100% independently) of potentially relevant articles for inclusion. Studies were selected for full document screening and data extraction based on the following criteria:

1.  \- Included a measure out-of-office blood pressure (home or ambulatory blood pressure).

2.  \- Included a measure of clinic blood pressure.

3.  \- A cross-sectional study examining data from a single time point.

4.  \- Examined independent variables routinely available or measurable in a primary care clinic setting.

5.  \- Examined the association between these variables and the home-clinic blood pressure difference, white coat or masked hypertension (outcome variable).

6.  \- Included primary data.

The review aimed to identify factors that could be utilized by clinicians in the routine diagnosis and management of hypertension in a Primary Care setting. Thus, studies were excluded from the review if they:

1.  \- Examined patients in hospital for surgery or treatment for a specialist condition (e.g., haemodialysis, pregnancy)

2.  \- Examined measurements taken in a nonclinical or pharmacy setting.

3.  \- Studied patients aged below 18 years.

Data collection {#s4}
---------------

Data were extracted from all relevant articles identified in the search strategy by J.P.S. and B.F. This included the study setting and population, basic patient demographics, clinic blood pressure, out-of-office blood pressure, and the outcome of interest (home-clinic blood pressure difference, white coat or masked effect, white coat or masked hypertension). Where a logistic regression analysis was performed examining the association between specific variables and the home-clinic blood pressure difference, relevant odds ratios (ORs) for each predictor of this difference were extracted. The form used for data extraction is available in the [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1).

During data extraction, the methodological quality and risk of bias of individual studies were assessed. This quality assessment covered domains of selection bias, detection bias, accuracy of measurement, analysis, and adjustment for confounding using a combination of questions from the QUADAS-2^[@CIT0023]^ and CASP^[@CIT0024]^ checklists for the assessment of cohort studies.

Statistical analysis {#s5}
--------------------

The primary outcome of this review was to identify the most important factors that predict a significant home-clinic blood pressure difference. This was defined by (a) the number of studies citing specific risk factors for the home-clinic blood pressure difference, white coat or masked hypertension and (b) a pooled OR for the most commonly cited predictors of white coat or masked hypertension. This pooled estimate was based on log OR estimates and their confidence intervals (CIs) synthesized in a random-effects meta-analysis using the method of DerSimonian and Laird.^[@CIT0025]^ This method allows for between-study heterogeneity in the true ORs and produces a pooled estimate and 95% CIs to summarize the association between independent predictors and white coat or masked hypertension. Where 95% CIs were not presented in an included article, they were estimated from the corresponding *P* values using the methods described by Altman and Bland.^[@CIT0026]^

Sensitivity analyses were conducted focusing on those high quality studies that identified and corrected their analysis for confounding variables including age and sex. Where sufficient data were available, further sensitivity analyses explored the association between independent predictors and white coat or masked hypertension defined according to ambulatory blood pressure (daytime or 24 hour) or home monitoring and in subgroup populations: unselected patients and those with diagnosed hypertension (in patients with hypertension, studies examined predictors of white coat hypertension or masked uncontrolled hypertension).^[@CIT0027]^

All analyses were conducted using STATA version 13.1 (MP parallel edition, StataCorp, College Station, TX). Data are presented as proportions of the total study population, means with SD or ORs with 95% CIs unless otherwise stated.

RESULTS {#s6}
=======

The search strategy identified 3,743 unique articles of which 70 were eligible for this review after title, abstract, and full text screening ([Figure 1](#F1){ref-type="fig"}). Studies were conducted in 27 different countries in a community, primary care or hospital outpatient setting ([Table 2](#T2){ref-type="table"}). A total of 86,167 patients (mean age 54.5 years) were examined, including 40,622 females (47%) and 40,840 patients on antihypertensive treatment. Study populations varied from unselected cohorts to those with normotension, hypertension, diabetes, or chronic kidney disease.

![Screening and selection of studies to include in analysis of predictors of the home-clinic blood pressure difference. Abbreviations: BMI, body mass index; sBP, systolic blood pressure; dBP, diastolic blood pressure.](ajhype_hpv157_f0001){#F1}

###### 

Characteristics of included studies

  Author                  Year    Country      Setting                Population                       Sample size   Mean age (years)   Sex (% female)   Out-of-office monitoring   Outcome of interest
  ----------------------- ------- ------------ ---------------------- -------------------------------- ------------- ------------------ ---------------- -------------------------- ------------------------------------
  Abir-Khalil *et al*.    2009    Morocco      Outpatient clinic      Admitted to cardiology unit      2,462         50.5               58%              ABPM                       White coat hypertension
  Afsar *et al*.          2013    Turkey       Outpatient clinic      Diabetic                         102           48.9               61%              ABPM                       Masked hypertension
  Akilli *et al*.         2014    Turkey       Outpatient clinic      Diabetic                         85            50.7               41%              ABPM                       Masked hypertension
  Andalib *et al*.        2010    Canada       Primary Care           Hypertensives                    2,728         60.3               55%              Home                       Masked hypertension
  Asayama *et al*.        2009    Japan        Community              Unselected                       395           63.5               70%              Home                       Masked hypertension
  Azizi *et al*.          2013    Morocco      Outpatient clinic      Normotensives                    438           47.3               49%              ABPM                       Masked hypertension
  Bakalakou *et al*.      2013    Greece       n/a                    Hypertensives                    305           57.2               59%              ABPM                       Masked nocturnal hypertension
  Barochiner *et al*.     2013    Argentina    Outpatient clinic      Hypertensives                    172           64.8               69%              Home                       Masked hypertension
  Ben-Dov *et al*.        2007a   Israel       Outpatient clinic      Referred for ABPM                3,928         55.1               53%              ABPM                       Home-clinic difference
  Ben-Dov *et al*.        2007b   Israel       Outpatient clinic      Referred for ABPM                3,957         54.8               58%              ABPM                       White coat and masked hypertension
  Bucio *et al*.          2011    Mexico       Outpatient clinic      Unselected                       49            40.9               53%              ABPM                       White coat hypertension
  Cacciolati *et al*.     2011    France       Community              Unselected                       690           78.8               65%              Home                       Masked hypertension
  Calvo-Vargas *et al*.   1999    Mexico       Outpatient clinic      n/a                              243           56.5               80 %             Home                       Home-clinic difference
  Charvat *et al*.        2010    Czech Rep.   n/a                    Diabetic                         64            ---                ---              ABPM                       Masked hypertension
  Dolan *et al*.          2004    Ireland      Outpatient clinic      Referred for ABPM                5,716         53.6               53%              ABPM                       White coat hypertension
  Florian *et al*.        2013    USA          Community              Unselected                       1,652         ---                ---              Home                       Masked hypertension
  Gorostidi *et al*.      2013    Spain        Primary Care/ clinic   Chronic kidney disease           5,693         67.0               42%              ABPM                       White coat and masked hypertension
  Gualdiero *et al*.      2000    UK           Outpatient clinic      Referred for ABPM                1,553         53.4               49%              ABPM                       Home-clinic difference
  Hanninen *et al*.       2011    Finland      Community              Unselected                       1,459         55.8               53%              Home                       Masked hypertension
  Hermida *et al*.        2004    Spain        n/a                    Hypertensives                    837           49.5               51%              ABPM                       Home-clinic difference
  Hernández del Ray       1996    Spain        Outpatient clinic      Hypertensives                    106           43.0               52%              ABPM                       White coat hypertension
  Hiraizumi *et al*.      1998    Japan        n/a                    Patients with raised office BP   86            ---                62%              ABPM                       Home-clinic difference
  Horikawa *et al*.       2008    Japan        Primary Care           Hypertensives                    3,308         66.2               56%              Home                       Home-clinic difference
  Hozawa *et al*.         2001    Japan        Community              Unselected                       1,789         ---                ---              Home                       Home-clinic difference
  Huang *et al*.          2010    Taiwan       Outpatient clinic      Hypertensives                    121           45.7               37%              ABPM                       Home-clinic difference
  Hwang *et al*.          2007    Korea        Outpatient clinic      Referred for ABPM                967           51.9               48%              ABPM                       White coat and masked hypertension
  Iimuro *et al*.         2013    Japan        Outpatient clinic      Chronic kidney disease           1,075         60.7               37%              ABPM                       Home-clinic difference
  Ishikawa *et al*.       2007    Japan        Outpatient clinic      Hypertensives                    405           66.9               45%              Home                       Masked (morning) hypertension
  Jhalani *et al*.        2005    USA          Outpatient clinic      Hypertensives                    226           52.0               53%              ABPM                       Home-clinic difference
  Kabutoya *et al*.       2009    Japan        Outpatient clinic      Hypertensives                    969           66.5               58%              Home                       Home-clinic difference
  Kayrak *et al*.         2010    Turkey       Outpatient clinic      Ungoing exercise testing         61            47.3               21%              ABPM                       Masked hypertension
  Kim *et al*.            2011    Korea        Community              Normotensives                    84            33.1               37%              ABPM                       Masked hypertension
  Koupil *et al*.         2005    Sweden       Community              Unselected (aged \~70 years)     736           70.9               0%               ABPM                       White coat and masked hypertension
  Labinson *et al*.       2008    USA          Primary Care           Patients with raised office BP   65            54.0               55%              ABPM                       Home-clinic difference
  Lee *et al*.            2008    Korea        Primary Care           Hypertensives                    4,435         57.1               51%              Home                       Masked hypertension
  Lerman *et al*.         1989    USA          Primary Care           Hypertensives                    98            54.6               43%              ABPM                       Home-clinic difference
  Lindbaek *et al*.       2003    Norway       Primary Care           Suspected/treated hypertension   221           58.0               48%              ABPM                       Home-clinic difference
  MacDonald *et al*.      1999    Canada       Outpatient clinic      Hypertensives                    103           59.3               47%              ABPM                       White coat hypertension
  Mallion *et al*.        2006    France       Primary Care           Hypertensives                    1,150         69.0               63%              Home                       Masked hypertension
  Manios *et al*.         2008    Greece       Outpatient clinic      Unselected                       2,004         50.9               53%              ABPM                       Home-clinic difference
  Mansoor *et al*.        1996    USA          Outpatient clinic      Hypertensives                    64            56.0               64%              ABPM                       Home-clinic difference
  Markis *et al*.         2009    Greece       Outpatient clinic      Unselected                       254           55.0               60%              ABPM                       Masked hypertension
  Martinez *et al*.       1999    Spain        Primary Care           Hypertensives                    345           51.8               52%              ABPM                       White coat hypertension
  Nasothimiou *et al*.    2012    Greece       Outpatient clinic      Referred for ABPM                613           53.0               43%              ABPM/Home                  White coat and masked hypertension
  Niiranen *et al*.       2006    Finland      Community              Unselected                       1,440         55.0               53%              Home                       White coat hypertension
  Obara *et al*.          2005    Japan        Primary Care           Hypertensives                    3,400         66.2               55%              Home                       White coat and masked hypertension
  Parati *et al*.         2012    Worldwide    Outpatient clinic      Unselected                       9,753         56.0               51%              ABPM                       Masked hypertension
  Park *et al*.           2011    Korea        Outpatient clinic      Hypertensives                    511           57.2               55%              Home                       Masked hypertension
  Rassmussen *et al*.     1998    Denmark      Outpatient clinic      Unselected                       1,855         ---                48%              ABPM                       Home-clinic difference
  Rodrigues *et al*.      2009    Brazil       n/a                    Diabetic                         566           49.1               47%              ABPM                       Home-clinic difference
  Sandvik *et al*.        1998    Norway       Primary Care           Hypertensives                    75            50.1               65%              Home                       White coat hypertension
  Schoenthaler *et al*.   2010    USA          Community              Normotensives                    240           35.9               61%              ABPM                       (Marked) masked hypertension
  Sheppard *et al*.       2014    UK           Primary Care           Hypertensives                    220           67.0               53%              Home                       White coat/masked effect
  Smirnova *et al*.       2009    Russia       n/a                    Hypertensives                    39            53.7               51%              ABPM                       Home-clinic difference
  Sobrino *et al*.        2013    Spain        Outpatient clinic      Normotensives                    485           43.1               55%              ABPM                       Masked hypertension
  Sobrino *et al*.        2011    Spain        Outpatient clinic      Hypertensives                    302           56.2               56%              ABPM                       Masked hypertension
  Spruill *et al*.        2007    USA          Outpatient clinic      Unselected                       214           51.7               55%              ABPM                       Home-clinic difference
  Streitel *et al*.       2011    USA          Outpatient clinic      Unselected                       252           45.2               53%              ABPM                       Home-clinic difference
  Sung *et al*.           2013    Taiwan       Community              Unselected                       1,257         53.0               47%              ABPM                       Home-clinic difference
  Tam *et al*.            2007    Hong Kong    Primary Care           Referred for ABPM                617           52.9               ---              ABPM                       White coat hypertension
  Tardif *et al*.         2009    Canada       Primary Care           Hypertensives                    3,247         ---                ---              Home                       Masked hypertension
  Thomas *et al*.         2012    UK           Outpatient clinic      Unselected                       2,381         56.0               53%              ABPM                       Home-clinic difference
  Trudel *et al*.         2009    Canada       Community              Unselected                       2,370         44.0               61%              ABPM                       White coat and masked hypertension
  Tsai *et al*.           2003    Taiwan       n/a                    Unselected                       41            42.6               59%              ABPM                       Home-clinic difference
  Uze *et al*.            2012    Japan        Outpatient clinic      Diabetic                         193           62.7               55%              ABPM                       Masked hypertension
  Verdecchia *et al*.     2001    Italy        Outpatient clinic      Hypertensives                    1,546         39.0               34%              ABPM                       White coat hypertension
  Wang *et al*.           2007    China        Community              Unselected                       694           48.5               54%              ABPM                       White coat and masked hypertension
  Wing *et al*.           2002    Australia    Primary Care           Hypertensives                    713           72.0               47%              ABPM                       Masked hypertension
  Yoon *et al*.           2012    Korea        Outpatient clinic      Hypertensives                    1,087         57.0               52%              Home                       Home-clinic difference
  Zhou *et al*.           2013    China        Outpatient clinic      Diabetic                         856           45.1               45%              ABPM                       Masked hypertension

References mentioned in the table are found in the [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1).

Abbreviations: ABPM, ambulatory blood pressure monitoring; Home, home blood pressure monitoring; BP, blood pressure.

Included studies varied in methodological quality with sampling strategies and the representativeness of the study population described in only 21/70 studies ([Supplementary Table 2](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1)). Most studies (55/57) defined the threshold for white coat or masked hypertension (where appropriate) and examined the home-clinic blood pressure difference as the primary focus of the study (68/70). Forty-six studies identified important confounding variables and 44 of these corrected for this confounding in their analysis. Full details of the multivariate analysis conducted in each study are given in [Supplementary Table 3](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1)).

Included studies reported a total of 60 significant predictors of the home-clinic blood pressure difference, white coat or masked hypertension. The most commonly cited predictors of the home-clinic blood pressure difference were sex (14 studies), age (11 studies), body mass index (BMI, 7 studies), and systolic (12 studies) and diastolic blood pressure (5 studies) ([Supplementary Table 4](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1)). These factors were also commonly cited as predictors of both white coat and masked hypertension with the addition of diabetes and smoking status ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The overall association between these factors and white coat or masked hypertension was established by pooling ORs for each predictor from 31 studies in a random-effects meta-analysis. Male sex (OR 1.47, 95% CI 1.18--1.75), increasing BMI (per kg/m^2^ increase, OR 1.07, 95% CI 1.01--1.14), current smoking status (OR 1.32, 95% CI 1.13--1.50), and systolic clinic blood pressure (per 1mm Hg increase, OR 1.10, 95% CI 1.01--1.19) were all found to be significant predictors of masked hypertension ([Figure 2](#F2){ref-type="fig"}). Male sex was found to be predictive of not having white coat hypertension (OR 0.57, 95% CI 0.42--0.72) ([Figure 3](#F3){ref-type="fig"}): analyzed with male sex as the reference, female sex was a significant predictor of white coat hypertension (OR 3.38, 95% CI 1.64--6.96). The heterogeneity between studies for sex (*I* ^2^ = 70.4% (masked hypertension); *I* ^2^ = 75.7% (white coat hypertension)), BMI (*I* ^2^ = 62.0%), and systolic blood pressure (*I* ^2^ = 81.4%) predictors of white coat and masked hypertension was significant (*P* \< 0.05).

###### 

Predictors of masked hypertension reported in included studies (*n* = 34)

  ------------------------------
  ![](ajhype_hpv157_t0003.jpg)
  ------------------------------

Last row indicates total number of studies citing each factor as a significant predictor of masked hypertension. References mentioned in the table are found in the [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1).

Abbreviations: CVD, cardiovascular disease; PVD, peripheral vascular disease; BP, blood pressure; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; HT, hypertension; BMI, body mass index.

^a^Examined masked nocturnal hypertension as the outcome. ^b^Examined masked morning hypertension as the outcome. ^c^Examined "marked" masked hypertension as the outcome.

Significant predictor.

Nonsignificant predictor.

Significant predictor defined as an OR or *ß* coefficient with an associated *P* value of \<0.05.

###### 

Predictors of white coat hypertension reported in included studies (*n* = 18)

  ------------------------------
  ![](ajhype_hpv157_t0004.jpg)
  ------------------------------

Last row indicates total number of studies citing each factor as a significant predictor of masked hypertension. References mentioned in the table are found in the [Supplementary Appendix](http://ajh.oxfordjournals.org/lookup/suppl/doi:10.1093/ajh/hpv157/-/DC1).

Abbreviations: CVD, cardiovascular disease; BP, blood pressure; BMI, body mass index.

^a^Examined using the Centre for Epidemiological Studies Depression Scale.

Significant predictor.

Nonsignificant predictor.

Significant predictor defined as an OR or *ß* coefficient with an associated *P* value of \<0.05.

![Forest-plot showing pooled odds ratio estimates for the 7 most commonly cited predictors of masked hypertension. Abbreviations: MH, masked hypertension; CKD, chronic kidney disease. Binary predictors were defined using Female sex, no diabetes, and nonsmoker as the reference values (respectively). Continuous predictors were defined as increases in age per 10 years, BMI per 1kg/m^2^ and systolic/diastolic blood pressure per 1mm Hg.](ajhype_hpv157_f0002){#F2}

![Forest-plot showing pooled odds ratio estimates for the 7 most commonly cited predictors of white coat hypertension. WCH, white coat hypertension; CKD, chronic kidney disease. Binary predictors were defined using female sex, no diabetes, and nonsmoker as the reference values (respectively). Continuous predictors were defined as increases in age per 10 years, BMI per 1kg/m^2^, and systolic/diastolic blood pressure per 1mm Hg.](ajhype_hpv157_f0003){#F3}

Sensitivity analysis {#s7}
--------------------

Inclusion of only those studies that used ambulatory blood pressure to define masked hypertension resulted in diabetes becoming a significant predictor (OR 1.42, 95% CI 1.22--1.61) but BMI and systolic blood pressure no longer being predictive. When only studies that used home blood pressure to define masked hypertension were included, only sex remained a significant predictor, although there were insufficient studies to examine the relationship between BMI and masked hypertension. Using ambulatory blood pressure or home blood pressure to define white coat hypertension had no impact on the findings of the primary analysis although there were no longer sufficient data to examine the association with diabetes, smoking status and diastolic blood pressure (studies using ambulatory blood pressure), or age, BMI, and systolic and diastolic blood pressure (studies using home blood pressure). Similar findings were observed in the sensitivity analysis excluding low quality studies that did not account for confounding variables.

In an unselected population, male sex and diabetes were predictive of masked hypertension (OR 1.76, 95% CI 1.29--2.24 (sex); OR 1.48, 95% CI 1.22--1.70 (diabetes)), while in hypertensive patients, only male sex remained significant (OR 1.52, 95% CI 1.11--1.93) for masked uncontrolled hypertension, although there were no longer sufficient data to examine the association with systolic and diastolic blood pressure. Examining only patients from an unselected population, male sex was predictive of not having white coat hypertension (OR 0.47, 95% CI 0.33--0.61) and systolic blood pressure was predictive of having white coat hypertension (OR 1.06, 95% CI 1.04--1.08). In hypertensive patients, male sex remained predictive of not having white coat hypertension (OR 0.62, 95% CI 0.48--0.76), although again, insufficient data were available to examine associations with BMI and systolic or diastolic blood pressure. The observed heterogeneity was not reduced in any sensitivity analyses examining studies by outcome measurement, sample populations, or methodological quality.

DISCUSSION {#s8}
==========

This study has systematically reviewed all existing literature evaluating the association between patient characteristics and the home-clinic blood pressure difference. A large number of studies were identified examining a number of common factors which predict the home-clinic blood pressure difference or white coat or masked hypertension. Meta-analyses of the most commonly cited predictors revealed that sex, BMI, smoking status, and systolic blood pressure level were the most important predictors, although these associations were mediated by the method of out-of-office blood pressure monitoring and the population studied. There is scope to incorporate such predictors into a clinical prediction tool which could be used to identify those patients more likely to display a significant masked or white coat effect and therefore better target the use of out-of-office blood pressure monitoring in routine clinical practice.

Strengths and limitations {#s9}
-------------------------

This is the largest systematic review to date of studies examining the association between patient factors and the home-clinic blood pressure difference. An extensive search strategy was used in multiple research literature databases to comprehensively capture all published articles relating to the study research question. Not all of the identified studies were directly comparable due to a lack of relevant data or the use of different statistical methods in the original study analyses. Thus, only 31/70 studies could be included in the meta-analysis. While sufficient data were available to analyze the primary outcome of this review, the lower number of studies eligible for meta-analysis meant some sensitivity and subgroup analyses were not possible. For instance, previous studies have suggested that the degree of white coat or masked effect may be affected by attributes of the person taking the clinic blood pressure measurement.^[@CIT0028]^ Although an attempt was made to extract details of the person taking clinic blood pressure from each included study, many did not report this or used both doctors and nurses to take readings without distinguishing between the 2, meaning a subgroup analysis by the type of person taking the clinic measurement was not possible.

The methodological quality of studies and the population of study varied widely between included studies and this may have contributed to the observed statistical heterogeneity. Indeed, the significant predictors of masked hypertension changed in sensitivity analyses excluding low quality studies that did not correct for confounding variables, although the statistical heterogeneity between studies remained significant. Only sex remained a significant predictor of both white coat and masked hypertension across patient populations and study quality.

Comparison with previous literature {#s10}
-----------------------------------

A number of previous reviews^[@CIT0020]^ and clinical guidelines^[@CIT0014]^ have discussed possible predictors of white coat and masked hypertension. Indeed, the present review demonstrates that the literature is becoming saturated with studies describing predictors of white coat or masked hypertension. Despite the large volume of articles studying this topic, little insight has been gained over the last 20 years and the patient factors commonly cited as significant predictors of the home-clinic blood pressure difference remain the same: age, sex, BMI, smoking status, and clinic blood pressure level.

Recent studies have examined the influence of patient ethnicity on the home-clinic blood pressure difference. Martin *et al.,* ^[@CIT0029]^ studied 770 individuals of White British, South Asian, or African-Caribbean ethnicity and found that when clinic blood pressure was defined using a single reading, non-hypertensive South Asian or African-Caribbean patients displayed less of a home-clinic blood pressure difference compared to White British patients. In contrast, hypertensive patients of South Asian or African-Caribbean origin had a greater home-clinic difference. The present review found only 2 studies examining ethnicity as a predictor of the home-clinic blood pressure difference^[@CIT0030],[@CIT0031]^ and neither could be included in the meta-analysis. However, the recent Jackson Heart study^[@CIT0032]^ (published after the searches in the present study were conducted) examined a population of 972 African-Americans and found male sex, current smoking status, diabetes, prescribed medication, and clinic blood pressure were significant predictors of masked hypertension. These findings are similar to those of the present review and suggest that our findings may be applicable to some ethnic minority groups.

This is the first systematic review to summarize all available evidence and present pooled estimates describing the most important predictors of white coat and masked hypertension. Seventy studies fulfilled our strict inclusion criteria and 60 different predictors of the home-clinic blood pressure difference were identified. It is unclear from the data included in this review as to why certain factors predict a white coat or masked effect to a greater degree than others. However, it is of interest that, in our analysis, significant predictors appeared to be related to the underlying cardiovascular disease risk associated with each condition: masked hypertension (associated with high cardiovascular disease risk)^[@CIT0018],[@CIT0019]^ was more common in patients with characteristics associated with increased cardiovascular risk such as male sex, current smoking status, increasing BMI, and increasing blood pressure.^[@CIT0033],[@CIT0034]^ White coat hypertension (associated with lower cardiovascular disease risk)^[@CIT0018],[@CIT0019]^ was associated with female sex, which is also associated with lower cardiovascular disease risk (compared to male sex).^[@CIT0033],[@CIT0034]^

Implications for clinical practice {#s11}
----------------------------------

It is important to identify patients with white coat and masked hypertension because failure to do so can result in significant misdiagnosis and mismanagement of hypertension.^[@CIT0035]^ Those with white coat hypertension may be prescribed therapy when they do not need it while patients with masked hypertension are likely to be denied potentially beneficial treatment.^[@CIT0015]^ Despite the large number of studies citing predictors of white coat and masked hypertension identified in this review, few have proposed a practical method for screening patients in routine clinical practice.^[@CIT0021]^ Indeed, screening for white coat or masked hypertension is only useful if it reduces the number of patients potentially eligible for out-of-office monitoring. The number of predictive factors identified in this review makes their use to guide targeting of out-of-office monitoring impractical because a significant proportion of patients attending routine clinical practice are likely to present with at least one of these characteristics.

Some previous studies have suggested methods for targeted use of ABPM, mostly suggesting specific clinic blood pressure thresholds to target monitoring.^[@CIT0036],[@CIT0037]^ Viera *et al.* ^[@CIT0038]^ examined optimal clinic blood pressure levels for referral for ambulatory monitoring in patients with normal clinic pressure for detection of masked hypertension. They identified a threshold of greater than 120/82mm Hg as optimal but concluded that using clinic blood pressure alone was not an effective method of triaging for out-of-office monitoring because of high referral rates and moderate specificity. They suggested that a combination of factors, perhaps such as those identified in the present review, might be more effective at targeting ABPM efficiently.

The European Society of Hypertension^[@CIT0014]^ suggests that practicing physicians consider screening for masked hypertension in high risk patients with normal clinic blood pressure, or screening for white coat hypertension in low risk patients with raised clinic blood pressure. This is still likely to result in a large number of patients being indicated for out-of-office blood pressure monitoring and future work should therefore focus on developing a single, practical, decision aid for targeted screening of white coat or masked hypertension, incorporating all of the significant predictors identified in this review.

There are a number of common patient characteristics that predict the home-clinic blood pressure difference including sex, current smoking status, increasing BMI, and increasing systolic blood pressure. There is scope to incorporate such predictors into a clinical prediction tool which could be used to identify those patients displaying a significant masked or white coat effect in routine clinical practice. Identification of such patients could help to better target antihypertensive treatment at those people with the most to gain.
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